Published in Gene Therapy Weekly, May 8th, 2003
"Delivery of DNA mixed with a degradable matrix carrier was supposed to improve transgene expression. Using a rabbit hind-limb ischemia model, we tested the angiogenic potency of plasmid encoding human vascular endothelial growth factor (pSG5-VEGF165) entrapped in fibrin sealant. Animals were injected intramuscularly with 500 mcg of pSG5-VEGF165 or control plasmid, dissolved in saline (PBS) or fibrin glue," scientists in Austria reported.
"After 14 days, presence of delivered constructs and expression of transgene was confirmed in injected muscles of all animals. There were no...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.